Pfizer (NYSE: PFE) has recorded the highest quarterly sales in its history.
The US pharma giant also beat second-quarter 2022 profit expectations on Thursday, with the remarkable figures coming thanks largely to sales of its COVID-19 pill Paxlovid (nirmatrelvir/ritonavir) and vaccine Comirnaty.
In total, revenues at Pfizer were $27.7 billion for the quarter, a 47% rise on the second quarter of 2021 and ahead of Wall Street estimates averaging $26.31 billion.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze